S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.
Abatacept
Biomarkers
C-Reactive protein (CRP)
Juvenile idiopathic arthritis
S100
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
25 Jun 2024
25 Jun 2024
Historique:
received:
20
09
2023
accepted:
26
05
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
25
6
2024
Statut:
epublish
Résumé
Juvenile idiopathic arthritis (JIA) comprises a heterogeneous group of conditions that can cause marked disability and diminished quality of life. Data on predictors of clinical response are insufficient to guide selection of the appropriate biologic agent for individual patients. This study aimed to investigate the propensity of S100A8/9 and S100A12 as predictive biomarkers of abatacept response in polyarticular-course juvenile idiopathic arthritis (pJIA). Data from a phase 3 trial (NCT01844518) of subcutaneous abatacept in patients with active pJIA (n = 219) were used in this exploratory analysis. Association between biomarker levels at baseline and improvements in JIA-American College of Rheumatology (ACR) criteria responses or baseline disease activity (measured by Juvenile Arthritis Disease Activity Score in 27 joints using C-reactive protein [JADAS27-CRP]) were assessed. Biomarker level changes from baseline to month 4 were assessed for disease outcome prediction up to 21 months. At baseline, 158 patients had available biomarker samples. Lower baseline S100A8/9 levels (≤ 3295 ng/mL) were associated with greater odds of achieving JIA-ACR90 (odds ratio [OR]: 2.54 [95% confidence interval (CI): 1.25-5.18]), JIA-ACR100 (OR: 3.72 [95% CI: 1.48-9.37]), JIA-ACR inactive disease (ID; OR: 4.25 [95% CI: 2.03-8.92]), JADAS27-CRP ID (OR: 2.34 [95% CI: 1.02-5.39]) at month 4, and JIA-ACR ID (OR: 3.01 [95% CI: 1.57-5.78]) at month 16. Lower baseline S100A12 levels (≤ 176 ng/mL) were associated with greater odds of achieving JIA-ACR90 (OR: 2.52 [95% CI: 1.23-5.13]), JIA-ACR100 (OR: 3.68 [95% CI: 1.46-9.28]), JIA-ACR ID (OR: 3.66 [95% CI: 1.76-7.61]), JIA-ACR90 (OR: 2.03 [95% CI: 1.07-3.87]), JIA-ACR100 (OR: 2.14 [95% CI: 1.10-4.17]), and JIA-ACR ID (OR: 4.22 [95% CI: 2.15-8.29]) at month 16. From baseline to month 4, decreases in S100A8/9 and S100A12 generally exceeded 50% among JIA-ACR90/100/ID responders. Lower baseline levels of S100A8/9 and S100A12 proteins predicted better response to abatacept treatment than higher levels and may serve as early predictive biomarkers in pJIA. Decreases in these biomarker levels may also predict longer-term response to abatacept in pJIA.
Sections du résumé
BACKGROUND
BACKGROUND
Juvenile idiopathic arthritis (JIA) comprises a heterogeneous group of conditions that can cause marked disability and diminished quality of life. Data on predictors of clinical response are insufficient to guide selection of the appropriate biologic agent for individual patients. This study aimed to investigate the propensity of S100A8/9 and S100A12 as predictive biomarkers of abatacept response in polyarticular-course juvenile idiopathic arthritis (pJIA).
METHODS
METHODS
Data from a phase 3 trial (NCT01844518) of subcutaneous abatacept in patients with active pJIA (n = 219) were used in this exploratory analysis. Association between biomarker levels at baseline and improvements in JIA-American College of Rheumatology (ACR) criteria responses or baseline disease activity (measured by Juvenile Arthritis Disease Activity Score in 27 joints using C-reactive protein [JADAS27-CRP]) were assessed. Biomarker level changes from baseline to month 4 were assessed for disease outcome prediction up to 21 months.
RESULTS
RESULTS
At baseline, 158 patients had available biomarker samples. Lower baseline S100A8/9 levels (≤ 3295 ng/mL) were associated with greater odds of achieving JIA-ACR90 (odds ratio [OR]: 2.54 [95% confidence interval (CI): 1.25-5.18]), JIA-ACR100 (OR: 3.72 [95% CI: 1.48-9.37]), JIA-ACR inactive disease (ID; OR: 4.25 [95% CI: 2.03-8.92]), JADAS27-CRP ID (OR: 2.34 [95% CI: 1.02-5.39]) at month 4, and JIA-ACR ID (OR: 3.01 [95% CI: 1.57-5.78]) at month 16. Lower baseline S100A12 levels (≤ 176 ng/mL) were associated with greater odds of achieving JIA-ACR90 (OR: 2.52 [95% CI: 1.23-5.13]), JIA-ACR100 (OR: 3.68 [95% CI: 1.46-9.28]), JIA-ACR ID (OR: 3.66 [95% CI: 1.76-7.61]), JIA-ACR90 (OR: 2.03 [95% CI: 1.07-3.87]), JIA-ACR100 (OR: 2.14 [95% CI: 1.10-4.17]), and JIA-ACR ID (OR: 4.22 [95% CI: 2.15-8.29]) at month 16. From baseline to month 4, decreases in S100A8/9 and S100A12 generally exceeded 50% among JIA-ACR90/100/ID responders.
CONCLUSION
CONCLUSIONS
Lower baseline levels of S100A8/9 and S100A12 proteins predicted better response to abatacept treatment than higher levels and may serve as early predictive biomarkers in pJIA. Decreases in these biomarker levels may also predict longer-term response to abatacept in pJIA.
Identifiants
pubmed: 38918871
doi: 10.1186/s13075-024-03347-0
pii: 10.1186/s13075-024-03347-0
doi:
Substances chimiques
Abatacept
7D0YB67S97
Biomarkers
0
Antirheumatic Agents
0
Calgranulin B
0
Calgranulin A
0
S100A12 Protein
0
S100A8 protein, human
0
S100A12 protein, human
0
S100A9 protein, human
0
S100 Proteins
0
Types de publication
Journal Article
Clinical Trial, Phase III
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
125Subventions
Organisme : National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH)
ID : P30 AR076316 and P30 AR070549
Informations de copyright
© 2024. The Author(s).
Références
Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.
doi: 10.1016/S0140-6736(07)60363-8
pubmed: 17336654
Oliveira S, Ravelli A, Pistorio A, Castell E, Malattia C, Prieur AM, Saad Magalhães C, Murray KJ, Bae SC, Joos R, et al. Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum. 2007;57(1):35–43.
doi: 10.1002/art.22473
pubmed: 17266064
Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Anton J, Avcin T, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819–28.
pubmed: 29643108
Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, Colbert RA, Feldman BM, Ferguson PJ, Gewanter H. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non‐systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717–34.
doi: 10.1002/acr.23870
pubmed: 31021516
Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, bud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–91.
doi: 10.1016/S0140-6736(08)60998-8
pubmed: 18632147
Brunner HI, Tzaribachev N, Vega-Cornejo G, Louw I, Berman A, Penadés IC, Antón J, Ávila‐Zapata F, Cuttica R, Horneff G. Subcutaneous abatacept in patients with polyarticular‐course juvenile idiopathic arthritis: results from a phase III open‐label study. Arthritis Rheumatol. 2018;70(7):1144–54.
doi: 10.1002/art.40466
pubmed: 29481737
pmcid: 6032847
Brunner HI, Wong R, Nys M, Kou TD, Dominique A, Martini A, Lovell DJ, Ruperto N, Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group. Abatacept: a review of the treatment of polyarticular-course juvenile idiopathic arthritis. Paediatr Drugs. 2020;22(6):653–72.
doi: 10.1007/s40272-020-00422-2
pubmed: 33029724
Brunner HI, Schanberg LE, Kimura Y, Dennos A, Co DO, Colbert RA, Fuhlbrigge RC, Goldmuntz E, Kingsbury DJ, Patty-Resk C, et al. New medications are needed for children with juvenile idiopathic arthritis. Arthritis Rheumatol. 2020;72(11):1945–51.
doi: 10.1002/art.41390
pubmed: 32524767
pmcid: 7722045
Choida V, Hall-Craggs M, Jebson BR, Fisher C, Leandro M, Wedderburn LR, Ciurtin C. Biomarkers of response to biologic therapy in juvenile idiopathic arthritis. Front Pharmacol. 2020;11:635823.
doi: 10.3389/fphar.2020.635823
pubmed: 33603671
Selvestrel D, Lucafo M, Pugnetti L, Pagarin S, Moressa V, Pastore S, Taddio A, Stocco G, Decorti G. Responses of patients with juvenile idiopathic arthritis to methotrexate: a genomic outlook. Expert Rev Clin Immunol. 2021;17(10):1131–42.
doi: 10.1080/1744666X.2021.1968833
pubmed: 34392756
Marenholz I, Lovering RC, Heizmann CW. An update of the S100 nomenclature. Biochim Biophys Acta. 2006;1763(11):1282–3.
doi: 10.1016/j.bbamcr.2006.07.013
pubmed: 16938360
Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, Vogl T, Roth J, Tak PP, Holzinger D. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):499–505.
doi: 10.1136/annrheumdis-2013-203923
pubmed: 24297376
Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, Horneff G, Kuis W, Sorg C, Roth J. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 2004;50(4):1286–95.
doi: 10.1002/art.20125
pubmed: 15077313
Aljaberi N, Tronconi E, Schulert G, Grom AA, Lovell DJ, Huggins JL, Henrickson M, Brunner HI. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatr Rheumatol Online J. 2020;18(1):7.
doi: 10.1186/s12969-020-0398-2
pubmed: 31948488
pmcid: 6966841
Roth J, Goebeler M, van den Bos C, Sorg C. Expression of calcium-binding proteins MRP8 and MRP14 is associated with distinct monocytic differentiation pathways in HL-60 cells. Biochem Biophys Res Commun. 1993;191(2):565–70.
doi: 10.1006/bbrc.1993.1255
pubmed: 8384844
Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther. 2011;13(5):R178.
doi: 10.1186/ar3503
pubmed: 22029973
pmcid: 3308113
Nordal HH, Brun JG, Halse AK, Jonsson R, Fagerhol MK, Hammer HB. The neutrophil protein S100A12 is associated with a comprehensive ultrasonographic synovitis score in a longitudinal study of patients with rheumatoid arthritis treated with adalimumab. BMC Musculoskelet Disord. 2014;15:335.
doi: 10.1186/1471-2474-15-335
pubmed: 25282581
pmcid: 4196044
Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, FitzGerald O, Roth J. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology. 2003;42(11):1383–9.
doi: 10.1093/rheumatology/keg385
pubmed: 12832707
Moncrieffe H, Ursu S, Holzinger D, Patrick F, Kassoumeri L, Wade A, Roth J, Wedderburn LR. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford). 2013;52(8):1467–76.
doi: 10.1093/rheumatology/ket152
pubmed: 23620557
Bagri NK, Karmakar S, Haldar P, Lodha R, Kabra SK. Role of serum MRP8/14 in predicting response to methotrexate in children with juvenile idiopathic arthritis. J Clin Rheumatol. 2021;27(8):e336–41.
doi: 10.1097/RHU.0000000000001406
pubmed: 32658390
Gohar F, Anink J, Moncrieffe H, Van Suijlekom-Smit LWA, Prince FHM, van Rossum MAJ, Dolman KM, Hoppenreijs E, Ten Cate R, Ursu S, et al. S100A12 is associated with response to therapy in juvenile idiopathic arthritis. J Rheumatol. 2018;45(4):547–54.
doi: 10.3899/jrheum.170438
pubmed: 29335345
pmcid: 5880729
Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202–9.
doi: 10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R
pubmed: 9214419
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.
pubmed: 14760812
Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, Tortorelli A, Landgraf JM, Singh G, Martin M, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol. 2001;19(4 Suppl 23):S1–9.
pubmed: 11510308
Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929–36.
doi: 10.1002/acr.20497
pubmed: 21717596
Nordal EB, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, Lahdenne P, Nielsen S, Peltoniemi S, Straume B, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a nordic population-based setting. Ann Rheum Dis. 2012;71(7):1122–7.
doi: 10.1136/annrheumdis-2011-200237
pubmed: 22258487
Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658–66.
doi: 10.1002/art.24516
pubmed: 19405003
Consolaro A, Ravelli A. Defining criteria for disease activity states in juvenile idiopathic arthritis. Oxford University Press; 2016.
doi: 10.1093/rheumatology/kev414
Caruso JC, Cliff N. Empirical size, coverage, and power of confidence intervals for Spearman’s rho. Educ Psychol Meas. 1997;57(4):637–54.
doi: 10.1177/0013164497057004009
Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, Wulffraat N, Wedderburn L, Stanevicha V, Mihaylova D, et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis. 2012;71(12):1991–7.
doi: 10.1136/annrheumdis-2012-201329
pubmed: 22689317
Rothmund F, Gerss J, Ruperto N, Dabritz J, Wittkowski H, Frosch M, Wulffraat NM, Wedderburn LR, Holzinger D, Gohar F, et al. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2014;66(6):949–55.
doi: 10.1002/acr.22248
pubmed: 24339418
Hinze CH, Foell D, Johnson AL, Spalding SJ, Gottlieb BS, Morris PW, Kimura Y, Onel K, Li SC, Grom AA, et al. Serum S100A8/A9 and S100A12 levels in children with polyarticular forms of juvenile idiopathic arthritis: relationship to maintenance of clinically inactive disease during anti-tumor necrosis factor therapy and occurrence of disease flare after discontinuation of therapy. Arthritis Rheumatol. 2019;71(3):451–9.
doi: 10.1002/art.40727
pubmed: 30225949
pmcid: 6393224
Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, Stanevicha V, Mihaylova D, Ferriani V, Tsakalidou FK, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303(13):1266–73.
doi: 10.1001/jama.2010.375
pubmed: 20371785
Gerss J, Tedy M, Klein A, Horneff G, Miranda-Garcia M, Kessel C, Holzinger D, Stanevica V, Swart JF, Cabral DA, et al. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Ann Rheum Dis. 2022;81(7):990–7.
doi: 10.1136/annrheumdis-2021-222029
pubmed: 35260388
Hinze T, Kessel C, Hinze CH, Seibert J, Gram H, Foell D. A dysregulated interleukin-18-interferon-γ-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2021;60(11):5165–74.
doi: 10.1093/rheumatology/keab113
pubmed: 33576397
La C, Le PQ, Ferster A, Goffin L, Spruyt D, Lauwerys B, Durez P, Boulanger C, Sokolova T, Rasschaert J, et al. Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis. RMD Open. 2021;7(2):e001646.
doi: 10.1136/rmdopen-2021-001646
pubmed: 34108235
pmcid: 8191626
Ruperto N, Lovell DJ, Berman A, Anton J, Viola DO, Lauwerys B, Rama ME, Bohnsack J, Breedt J, Fischbach M, et al. Abatacept as monotherapy and in combination with methotrexate in patients with juvenile idiopathic arthritis: analysis of 2 phase III trials. J Rheumatol. 2023;50(11):1471–80.
doi: 10.3899/jrheum.2022-1320
pubmed: 37453737
World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277(11):925–6.
doi: 10.1001/jama.1997.03540350075038